|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00631917 |
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
Condition | Intervention | Phase |
Hypertension |
Drug: Aliskiren Drug: Ramipril |
Phase IV |
MedlinePlus related topics: | High Blood Pressure |
Drug Information available for: | Ramipril Aliskiren |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 54 Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study Evaluating the Long-Term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension |
Estimated Enrollment: | 640 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
Aliskiren 150mg, or 300mg, oral, once per day.
|
Drug: Aliskiren
Aliskiren 150mg, or 300mg, oral, once per day.
|
2: Active Comparator
Ramipril 5mg, or 10 mg, oral, once per day
|
Drug: Ramipril
Ramipril 5mg, or 10 mg, oral, once per day
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Missouri | |||||
Investigative Site | |||||
Kansas City, Missouri, United States | |||||
Argentina | |||||
Investigative Site | |||||
Investigative Site, Argentina | |||||
Colombia | |||||
Investigative Site | |||||
Investigative Site, Colombia | |||||
France | |||||
Investigative Site | |||||
Investigative Site, France | |||||
Germany | |||||
Investigative Site | |||||
Investigative Site, Germany | |||||
India | |||||
Investigative Site | |||||
investigative Site, India | |||||
Peru | |||||
Investigative Site | |||||
Investigative Site, Peru | |||||
Spain | |||||
Investigative Site | |||||
Investigative Site, Spain |
Novartis |
Study Chair: | Novartis | 862-778-8300 |
Responsible Party: | Novartis ( Novartis ) |
Study ID Numbers: | CSPP100A2404 |
First Received: | March 3, 2008 |
Last Updated: | August 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00631917 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|